Bronchodilator Drugs - Lebanon | Statista Market Forecast

Lebanon is expected to witness a significant growth in the revenue of the Bronchodilator Drugs market.
By 2024, the projected revenue is estimated to reach US$7.44m.
This growth is expected to continue with an annual growth rate (CAGR 2024-2029) of 2.47%, resulting in a market volume of US$8.41m by 2029.
When compared globally, United States is set to generate the highest revenue in the Bronchodilator Drugs market.
In 2024, United States is projected to generate a revenue of US$17.34bn.
Despite economic challenges, Lebanon's demand for bronchodilator drugs remains high due to the prevalence of respiratory diseases in the country.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are widely used in Lebanon to treat respiratory illnesses such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. These drugs help to relax the muscles in the airways, making it easier for individuals to breathe.

Customer preferences: In Lebanon, there is a growing preference for combination bronchodilator drugs over single bronchodilator drugs. Combination drugs are more effective in treating respiratory illnesses and are more convenient for patients who only need to take one medication instead of multiple. Additionally, there is a preference for inhalers over oral medication as they provide faster relief and are more targeted to the affected area.

Trends in the market: The Bronchodilator Drugs market in Lebanon is experiencing steady growth due to the increasing prevalence of respiratory illnesses. The market is expected to continue to grow as the population ages and the number of smokers increases. There is also a trend towards more personalized medicine, with doctors prescribing specific bronchodilator drugs based on the patient's individual needs and medical history.

Local special circumstances: One of the unique aspects of the Bronchodilator Drugs market in Lebanon is the high prevalence of smoking. This has led to a higher incidence of respiratory illnesses, particularly among men. Additionally, the country's air pollution levels are high, which further exacerbates respiratory issues. These factors contribute to a higher demand for bronchodilator drugs in Lebanon.

Underlying macroeconomic factors: Lebanon's healthcare system is characterized by a high level of out-of-pocket spending, which can make it difficult for some individuals to afford bronchodilator drugs. However, the government has taken steps to improve access to healthcare, including implementing a National Health Strategy that aims to provide universal health coverage. Additionally, the country has a strong pharmaceutical industry, which helps to ensure a steady supply of bronchodilator drugs. Overall, the Bronchodilator Drugs market in Lebanon is expected to continue to grow as demand for these medications increases.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.